Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

Genetic differences in individuals with regard to opioid-receptor signaling create clinical difficulties for opioid treatment; consequently, useful pharmacodynamic and predictive biomarkers are needed. In this prospective study, we studied gene expression changes in peripheral blood leukocytes using a microarray and real-time RT-PCR analysis to identify pharmacodynamic biomarkers for monitoring the effect of morphine in a cohort of opioid-treatment-naïve cancer patients. We also examined genetic variations in opioid receptor mu 1 (OPRM1, 118A→G) and catechol-O-methyltransferase (COMT, 472G→A) to evaluate predictive biomarkers of the treatment outcome of morphine. The plasma concentration of morphine was measured using a liquid chromatography-tandem mass spectrometry method. Microarray analysis revealed that the mRNA expression levels of arrestin β 1 (ARRB1) were significantly down-regulated by morphine treatment. Real-time RT-PCR analysis against independent samples confirmed the results (P=0.003) and changes during treatment were negatively correlated with the plasma morphine concentration (R=-0.42). No correlation was observed between the genotype of OPRM1 and morphine treatment; however, the plasma concentration of morphine and the required dose of morphine were significantly lower for the A/A genotype of COMT (vs. A/G+G/G, P=0.008 and 0.03). We found that changes in the expression of ARRB1 may be a novel pharmacodynamic biomarker and the COMT 472G→A genotype may be a predictive biomarker of the response to morphine treatment.

[1]  D. Rujescu,et al.  Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. , 2011, Journal of psychiatric research.

[2]  P. Hamet,et al.  Genetics of pain, opioids, and opioid responsiveness. , 2010, Metabolism: clinical and experimental.

[3]  J. Lieberman,et al.  The catechol-O-methyl-transferase gene in tardive dyskinesia , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[4]  R. Kaiser,et al.  Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors , 2010, Molecular Cancer Therapeutics.

[5]  Kaoru Tanaka,et al.  FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. , 2010, Cancer research.

[6]  Jörn Lötsch,et al.  Genetic modulation of the pharmacological treatment of pain. , 2009, Pharmacology & therapeutics.

[7]  N. Saijo,et al.  mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. , 2009, Cancer research.

[8]  T. Gotoda,et al.  Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples , 2008, Cancer science.

[9]  S. Kaasa,et al.  Genetic variation in the Catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer patients with pain , 2008, Molecular pain.

[10]  Ladislav Hosák,et al.  Role of the COMT gene Val158Met polymorphism in mental disorders: A review , 2007, European Psychiatry.

[11]  E. Bruera,et al.  Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene , 2007, PAIN.

[12]  Lan Ma,et al.  β-arrestin signaling and regulation of transcription , 2007, Journal of Cell Science.

[13]  Monique Ernst,et al.  Imaging genomics applied to anxiety, stress response, and resiliency , 2007, Neuroinformatics.

[14]  S. Allouche,et al.  Tracking the opioid receptors on the way of desensitization. , 2006, Cellular signalling.

[15]  S. Kaasa,et al.  The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients , 2005, Pain.

[16]  Marc G Caron,et al.  Desensitization of G protein-coupled receptors and neuronal functions. , 2004, Annual review of neuroscience.

[17]  M. Bouvier,et al.  Roles of G‐protein‐coupled receptor dimerization , 2004, EMBO reports.

[18]  Joshua A. Bueller,et al.  COMT val158met Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain Stressor , 2003, Science.

[19]  R. Schulz,et al.  Chronic Morphine Treatment Inhibits Opioid Receptor Desensitization and Internalization , 2002, The Journal of Neuroscience.

[20]  Richard R. Neubig,et al.  Regulators of G-Protein signalling as new central nervous system drug targets , 2002, Nature Reviews Drug Discovery.

[21]  H. Ueda,et al.  Protein Kinase C-Mediated Inhibition of μ-Opioid Receptor Internalization and Its Involvement in the Development of Acute Tolerance to Peripheral μ-Agonist Analgesia , 2001, The Journal of Neuroscience.

[22]  P. Sánchez-Blázquez,et al.  RGS9 proteins facilitate acute tolerance to mu‐opioid effects , 2001, The European journal of neuroscience.

[23]  H. Ueda,et al.  Protein kinase C-mediated inhibition of mu-opioid receptor internalization and its involvement in the development of acute tolerance to peripheral mu-agonist analgesia. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  E. Nestler,et al.  Effects of regulators of G protein-signaling proteins on the functional response of the mu-opioid receptor in a melanophore-based assay. , 1999, The Journal of pharmacology and experimental therapeutics.

[25]  L. Jan,et al.  Functional Dissociation of μ Opioid Receptor Signaling and Endocytosis Implications for the Biology of Opiate Tolerance and Addiction , 1999, Neuron.

[26]  Brigitte L. Kieffer,et al.  Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.

[27]  R. Lefkowitz,et al.  Desensitization of G protein-coupled receptors. , 1996, Recent progress in hormone research.

[28]  B. Bainbridge,et al.  Genetics , 1981, Experientia.